- Home
- MUFG vs AMGN Comparison
MUFG vs AMGN Comparison
Compare MUFG & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUFG
- AMGN
- Stock Information
- Founded
- MUFG 1880
- AMGN 1980
- Country
- MUFG Japan
- AMGN United States
- Employees
- MUFG N/A
- AMGN N/A
- Industry
- MUFG Commercial Banks
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MUFG Finance
- AMGN Health Care
- Exchange
- MUFG Nasdaq
- AMGN Nasdaq
- Market Cap
- MUFG 141.2B
- AMGN 155.9B
- IPO Year
- MUFG 2001
- AMGN N/A
- Fundamental
- Price
- MUFG $13.70
- AMGN $277.13
- Analyst Decision
- MUFG
- AMGN Hold
- Analyst Count
- MUFG 0
- AMGN 20
- Target Price
- MUFG N/A
- AMGN $322.30
- AVG Volume (30 Days)
- MUFG 3.9M
- AMGN 2.7M
- Earning Date
- MUFG 07-31-2025
- AMGN 08-05-2025
- Dividend Yield
- MUFG 0.98%
- AMGN 3.41%
- EPS Growth
- MUFG 44.22
- AMGN 56.16
- EPS
- MUFG 1.06
- AMGN 10.94
- Revenue
- MUFG $53,454,060,035.00
- AMGN $34,126,000,000.00
- Revenue This Year
- MUFG $11.01
- AMGN $7.73
- Revenue Next Year
- MUFG $16.96
- AMGN $1.68
- P/E Ratio
- MUFG $12.71
- AMGN $25.52
- Revenue Growth
- MUFG 53.24
- AMGN 15.56
- 52 Week Low
- MUFG $8.75
- AMGN $253.30
- 52 Week High
- MUFG $15.03
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- MUFG 56.98
- AMGN 42.37
- Support Level
- MUFG $13.52
- AMGN $267.83
- Resistance Level
- MUFG $13.81
- AMGN $286.17
- Average True Range (ATR)
- MUFG 0.17
- AMGN 7.34
- MACD
- MUFG -0.03
- AMGN -1.85
- Stochastic Oscillator
- MUFG 91.54
- AMGN 29.37
About MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets, with an 8.0% share of all domestic loans as of March 2024. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.